.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
US Department of Justice
Deloitte
Merck
Cipla
Julphar
Covington
UBS
Baxter

Generated: June 25, 2017

DrugPatentWatch Database Preview

Azithromycin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for azithromycin and what is the scope of azithromycin patent protection?

Azithromycin
is the generic ingredient in five branded drugs marketed by Hospira, Lupin Ltd, Gland Pharma Ltd, Wockhardt, Sagent Strides, Apotex Corp, Teva Parenteral, Sandoz, Pfizer, Oak Pharms Inc, Pliva, Teva Pharms, Sun Pharm Inds Ltd, Mylan Labs Ltd, Teva, Mylan, Pliva Hrvatska Doo, Fresenius Kabi Usa, Aurobindo Pharma Ltd, and Pf Prism Cv, and is included in forty-five NDAs. There are ten patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Azithromycin has two hundred and ten patent family members in sixty-three countries.

There are thirty-one drug master file entries for azithromycin. Fifty-five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: azithromycin

Tradenames:5
Patents:10
Applicants:20
NDAs:45
Drug Master File Entries: see list31
Suppliers / Packagers: see list55
Bulk Api Vendors: see list40
Clinical Trials: see list296
Patent Applications: see list5,296
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:azithromycin at DailyMed

Pharmacology for Ingredient: azithromycin

Ingredient-typeMacrolides
Drug ClassMacrolide Antimicrobial

Tentative approvals for AZITHROMYCIN

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe1%SOLUTION; OPHTHALMIC
► Subscribe► Subscribe500MGINJECTABLE;INJECTION
► Subscribe► Subscribe200MG/5MLSUSPENSION;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
ZITHROMAX
azithromycin
FOR SUSPENSION;ORAL050693-001Sep 28, 1994RXYesYes6,268,489► SubscribeY ► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes7,056,893► SubscribeY ► Subscribe
Mylan
AZITHROMYCIN
azithromycin
TABLET;ORAL065365-001May 30, 2007ABRXNoNo► Subscribe► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes6,569,443► SubscribeY ► Subscribe
Pfizer
ZITHROMAX
azithromycin
TABLET;ORAL050711-001Jul 18, 1996ABRXYesNo6,268,489► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: azithromycin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 20056,068,859► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 20075,192,535► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: azithromycin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,970Topical treatment of prevention of ocular infections► Subscribe
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
7,108,865Controlled-release dosage forms of azithromycin► Subscribe
6,699,492 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: azithromycin

Country Document Number Estimated Expiration
India168879► Subscribe
Australia1303699► Subscribe
New Zealand283160► Subscribe
Germany69524214► Subscribe
European Patent Office1028707► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Merck
Citi
Fuji
Novartis
Teva
Dow
Cipla
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot